145 related articles for article (PubMed ID: 18612079)
1. Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Verhulst A; Sayer R; De Broe ME; D'Haese PC; Brown CD
Mol Pharmacol; 2008 Oct; 74(4):1084-91. PubMed ID: 18612079
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
Verhulst A; D'Haese PC; De Broe ME
J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
[TBL] [Abstract][Full Text] [Related]
3. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Whaley-Connell AT; Morris EM; Rehmer N; Yaghoubian JC; Wei Y; Hayden MR; Habibi J; Stump CS; Sowers JR
Am J Nephrol; 2007; 27(1):15-23. PubMed ID: 17204833
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Corna D; Sangalli F; Cattaneo D; Carrara F; Gaspari F; Remuzzi A; Zoja C; Benigni A; Perico N; Remuzzi G
Am J Nephrol; 2007; 27(6):630-8. PubMed ID: 17851231
[TBL] [Abstract][Full Text] [Related]
6. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Gazi I; Kostara C; Bairaktari ET; Elisaf M
J Clin Pharmacol; 2006 Nov; 46(11):1337-43. PubMed ID: 17050799
[TBL] [Abstract][Full Text] [Related]
8. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
10. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
Kostapanos MS; Milionis HJ; Saougos VG; Lagos KG; Kostara C; Bairaktari ET; Elisaf MS
J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):292-7. PubMed ID: 18172223
[TBL] [Abstract][Full Text] [Related]
14. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
15. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.
Ajith TA; Riji T; Anu V
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):625-9. PubMed ID: 18177480
[TBL] [Abstract][Full Text] [Related]
16. Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers.
Hua CX; Li YS; Liu YQ; Liu H; Li N; Wu Y; Xu L; Huang YL
Chin Med J (Engl); 2008 Jul; 121(13):1215-9. PubMed ID: 18710642
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells.
Fadini GP; Albiero M; Boscaro E; Menegazzo L; Cabrelle A; Piliego T; Federici M; Agostini C; Avogaro A
Cell Biol Int; 2010 Jul; 34(7):709-15. PubMed ID: 20233166
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
Ishibashi Y; Yamagishi S; Matsui T; Ohta K; Tanoue R; Takeuchi M; Ueda S; Nakamura K; Okuda S
Metabolism; 2012 Aug; 61(8):1067-72. PubMed ID: 22386936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
